#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Metastatic gastric cancer Primitive neuroectodermal tumour Cytomegalovirus infection Fallopian tube cancer Biotinidase deficiency Hodgkin's disease Spinal cord injury cervical Hypersomnia Acquired ATTR amyloidosis Encephalitis autoimmune Mantle cell lymphoma refractory Brain injury Hyperinsulinaemic hypoglycaemia Osteopetrosis Behcet's syndrome More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma – Diagnostics Angelman’s syndrome – Trials in Disease Rhabdomyosarcoma recurrent – Trials in Disease Paraneoplastic neurological syndrome – Basic Information Chronic granulomatous disease – Diagnostics VEXAS syndrome – Life with Disease Ocular melanoma – Trials in Disease Leiomyosarcoma recurrent – Trials in Disease Mantle cell lymphoma refractory – Treatment Angiosarcoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    OBI-821 Vinblastine Sulfate INF904 GSKVX000000030810 Levamlodipine Succinate Sodium Glycerophosphate Dronedarone Abc-35B-116 Anthoxanthum Odoratum INOBRODIB ASP3082 Utreloxastat Ulipristal Acetate Etoposide Alogliptin 177Lu-Dpi-4452 Naporafenib Gt005 Ascorbic Acid Bp IM-101 More therapies…

    Learn about Your Condition

    Leukaemia Ehlers-Danlos syndrome Short-bowel syndrome Vasospasm Renal transplant Acute myeloid leukaemia Pituitary tumour benign Acute respiratory failure Ureteric cancer Neurofibromatosis Crigler-Najjar syndrome Cerebrovascular accident Mucopolysaccharidosis III Anxiety Skin wrinkling More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Henri Mondor – 1 rue Gustave Eiffel

Hopital Henri Mondor – 1 rue Gustave Eiffel

51 Av Du Mal De Lattre De Tassigny, Creteil, 94000, France

Want to learn more about this study or check if you can participate? Contact us.

  • A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • ARLOCABTAGENE AUTOLEUCEL
    • Carfilzomib
    • Cyclophosphamide
    Austria Belgium Czechia Denmark Finland France +11

  • Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Belgium France Germany Italy Portugal

  • Effect of mitapivat versus placebo on transfusion burden in patients with sickle cell disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Anaemia
    Investigated Drugs:
    • Mitapivat
    Belgium France Italy

  • Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemtabrutinib
    • Obinutuzumab
    • Venetoclax
    France

  • Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Ly3484356
    • Anastrozole
    • Exemestane
    Austria Belgium Czechia Finland France Germany +10

  • A study to test if BHV-8000 is effective and safe for adults with early Parkinson’s disease

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Ioflupane (123I)
    Austria Belgium Czechia France Germany Italy +4

  • Study of drug combination with radiotherapy versus radiotherapy alone for locally advanced rectal cancer in patients 75 years and older

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Rectal adenocarcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Fluorouracil
    • Folinic Acid
    France

  • A Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Azacitidine
    • Ivosidenib
    France
Previous Page
1 … 3 4 5 6 7 … 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!